Data from OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

• DOI: 10.1158/0008-5472.c.6504491
• Publication Date: 2024-03-12T22:58:16Z
• Authors: Brendan D. Curti; Magdalena Kovacso...; Nicholas Morris; Edwin Walker; Lana Chisholm; Kevin Floyd; Joshua Walker; Iliana Gonzalez; Tanisha Meeuwsen; Bernard A. Fox; Tarsem Moudgil; William Miller; Daniel Haley; Todd Coffey; Brenda Fisher; Laurie Delanty-Mi...; Nicole Rymarchyk; Tracy Kelly; Todd Crocenzi; Eric Bernstein; Rachel Sanborn; Walter J. Urba; Andrew D. Weinberg

<div>Abstract<p>OX40 is a potent costimulatory receptor that can potentiate T-cell signaling on the surface of T lymphocytes, leading to their activation by specifically recognized antigen. In particular, OX40 engagement ligands present dendritic cells dramatically increases proliferation, effector function, and survival cells. Preclinical studies have shown agonists increase antitumor immunity improve tumor-free survival. this study, we performed phase I clinical trial using mouse monoclonal antibody (mAb) agonizes human in patients with advanced cancer. Patients treated one course anti-OX40 mAb showed an acceptable toxicity profile regression at least metastatic lesion 12 30 patients. Mechanistically, treatment increased B cell responses reporter antigen immunizations, led preferential upregulation CD4<sup>+</sup> FoxP3<sup>+</sup> regulatory tumor-infiltrating reactivity melanoma. Our findings clinically validate as immune-stimulating target for cancer, providing generalizable tool favorably influence properties circulating cells, intratumoral <i>Cancer Res; 73(24); 7189–98. ©2013 AACR</i>.</p></div>